Evaluation of Antiviral Activity of Ivermectin against Infectious Bovine Rhinotracheitis Virus in Rabbit Model

被引:3
|
作者
Wang, Chen [1 ,2 ,3 ,4 ,5 ]
Chen, Yingyu [1 ,2 ,3 ,4 ,5 ]
Chen, Xi [1 ,2 ,3 ,4 ,5 ]
Hu, Changmin [1 ,2 ,3 ,4 ,5 ]
Chen, Jianguo [1 ,2 ,3 ,4 ,5 ]
Guo, Aizhen [1 ,2 ,3 ,4 ,5 ]
机构
[1] Huazhong Agr Univ, Natl Key Lab Agr Microbiol, Wuhan 430070, Peoples R China
[2] Huazhong Agr Univ, Hubei Hongshan Lab, Wuhan 430070, Peoples R China
[3] Huazhong Agr Univ, Coll Vet Med, Wuhan 430070, Peoples R China
[4] Huazhong Agr Univ, Hubei Int Sci & Technol Cooperat Base Vet Epidemio, Wuhan 430070, Peoples R China
[5] Huazhong Agr Univ, Key Lab Dev Vet Diagnost Prod, Ruminant Bioprod, Minist Agr & Rural Affairs, Wuhan 430070, Peoples R China
来源
ANIMALS | 2023年 / 13卷 / 20期
关键词
ivermectin; infectious bovine rhinotracheitis; bovine herpes virus 1(BoHV-1); treatment; infectious bovine rhinotracheitis virus (IBRV); rabbits; DISPOSITION KINETICS; TRIGEMINAL GANGLIA; MOXIDECTIN; DORAMECTIN; HERPESVIRUS-1;
D O I
10.3390/ani13203164
中图分类号
S8 [畜牧、 动物医学、狩猎、蚕、蜂];
学科分类号
0905 ;
摘要
Infectious bovine rhinotracheitis (IBR) caused by bovine herpes virus 1 (BoHV-1) can lead to enormous economic losses in the cattle industry. Vaccine immunization is preferentially used to decrease its transmission speed and resultant clinical signs, rather than to completely stop viral infection. Therefore, a drug effective in treating IBR is urgently needed. Our previous work demonstrated that ivermectin significantly inhibited viral replication in a cell infection model. This study aimed to investigate its antiviral effects in vivo by using a rabbit infection model. The viral inhibition assay was first used to confirm that ivermectin at low concentrations (6-25 nM) could reduce viral titers (TCID50) significantly (p < 0.001) at 24 h post-infection. In rabbits, ivermectin was administrated with one to three doses, based on the recommended anti-parasite treatment dosage (0.2 mg/kg bodyweight) through subcutaneous injection at different days post-infection in the treated IBRV infection groups, while non-treated infection group was used as the control. The infected rabbits showed hyperthermia and other clinical signs, but the number of high-fever rabbits in the ivermectin treatment groups was significantly lower than that in the non-treated infection group. Furthermore, in ivermectin treatment groups, the cumulative clinical scores correlated negatively with drug doses and positively with delay of administration time post-infection. The overall nasal shedding time in ivermectin-treated groups was two days shorter than the non-treated challenge group. At the same time point, the titer of neutralizing antibodies in the treatment group with triple doses was higher than the other two-dose groups, but the difference between the treatment groups decreased with the delay of drug administration. Correspondingly, the serious extent of lung lesions was negatively related to the dosage, but positively related to the delay of drug administration. The qPCR with tissue homogenates showed that the virus was present in both the lung tissues and trigeminals of the infected rabbits. In conclusion, ivermectin treatment had therapeutic effect by decreasing clinical signs and viral shedding, but could not stop virus proliferation in lung tissues and trigeminals.
引用
收藏
页数:15
相关论文
共 38 条
  • [31] The in vitro Evaluation of the Activity of COVID-19 Antiviral Drugs Against Adenovirus
    Romanowski, Eric G.
    Yates, Kathleen A.
    Romanowski, John E.
    Shanks, Robert M. Q.
    Kowalski, Regis P.
    CLINICAL OPHTHALMOLOGY, 2021, 15 : 4787 - 4793
  • [32] Evaluation of the toxic effects of doramectin, ivermectin and eprinomectin against Triatoma infestans using a rat model
    Dade, Martin
    Daniele, Martin
    Mestorino, Nora
    BIOMEDICA, 2017, 37 (03): : 324 - 332
  • [33] Antiviral activity of silver nanoparticles against H1N1 influenza virus
    Seyfi, Manya
    Letafati, Arash
    Edalat, Fahime
    Malekshahi, Somayeh Shatizadeh
    Pirbonyeh, Neda
    Moattari, Afagh
    BMC RESEARCH NOTES, 2025, 18 (01)
  • [34] Assessing the Efficacy of VLP-Based Vaccine against Epstein-Barr Virus Using a Rabbit Model
    Reguraman, Narendran
    Hassani, Asma
    Philip, Pretty S.
    Pich, Dagmar
    Hammerschmidt, Wolfgang
    Khan, Gulfaraz
    VACCINES, 2023, 11 (03)
  • [35] Optimization and characterization of essential oil-loaded nanoemulsions for enhanced antiviral activity against tobacco mosaic virus (TMV) in tobacco plants
    Besati, Masoud
    Safarnejad, Mohammad Reza
    Aliahmadi, Atousa
    Farzaneh, Mohsen
    Rezadoost, Hassan
    Rafati, Hasan
    INDUSTRIAL CROPS AND PRODUCTS, 2024, 220
  • [36] Cetirizine from topical phosphatidylcholine liposomes: Evaluation of peripheral antihistaminic activity and systemic absorption in a rabbit model
    Elzainy, AAW
    Gu, XC
    Simons, FER
    Simons, KJ
    BIOPHARMACEUTICS & DRUG DISPOSITION, 2004, 25 (08) : 359 - 366
  • [37] A preliminary study of recombinant human interferon-α-2a activity against rabies virus in murine model
    Roy, S.
    Patil, D.
    Ghadigaonkar, S.
    Roy, R.
    Mukherjee, S.
    Chowdhary, A.
    Deshmukh, R.
    INDIAN JOURNAL OF MEDICAL MICROBIOLOGY, 2015, 33 (01) : 132 - 135
  • [38] Zygocotyle lunata as a model for in vivo screening of anthelmintic activity against paramphistomes: Evaluation of efficacy of praziquantel, albendazole and closantel in experimentally infected mice
    Pinto, Hudson A.
    Assis, Jordana C. A.
    Silva, Beatriz C. M.
    Goncalves, Nicole Q.
    Melo, Alan L.
    EXPERIMENTAL PARASITOLOGY, 2019, 199 : 74 - 79